OBJECTIVE: To determine the effect of plasma glucose lowering on coronary circulatory function in type 2 diabetes mellitus. METHODS: Twenty patients with type 2 diabetes and 18 weight-matched controls were studied. At baseline, myocardial blood flow (MBF) was measured with [(13)N]ammonia and positron emission tomography at rest, during cold pressor testing (CPT), and during adenosine hyperaemia. In diabetic patients, MBF and blood chemistry were analysed again after 3 months of glucose-lowering treatment with glyburide and metformin. RESULTS: Although hyperaemic MBF did not differ significantly between the patients and controls (1.81 (0.38) v 1.97 (0.43) ml/min/g; mean (SD)), the CPT-induced MBF increase (DeltaMBF) was significantly less in diabetic patients than in controls (0.07 (0.07) v 0.25 (0.12) ml/min/g; p<0.001). Treatment with glyburide and metformin significantly decreased plasma glucose concentrations from 207 (76) to 134 (52) mg/dl (p<0.001). This decrease in plasma glucose was paralleled by a significant increase in DeltaMBF in response to CPT (0.20 (0.16) from 0.07 (0.07) ml/min/g; p<0.001), which tended to be lower than in controls at baseline (0.20 (0.16) v 0.25 (0.12) ml/min/g; p = NS). The decrease in plasma glucose concentrations correlated significantly with the improvement in DeltaMBF in response to CPT (r = 0.67, p<0.01). CONCLUSIONS: Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin. The close association between the decrease in plasma glucose concentration and the improvement in coronary vasomotor function in response to CPT suggests a direct adverse effect of raised plasma glucose concentration on diabetes-related coronary vascular disease.
OBJECTIVE: To determine the effect of plasma glucose lowering on coronary circulatory function in type 2 diabetes mellitus. METHODS: Twenty patients with type 2 diabetes and 18 weight-matched controls were studied. At baseline, myocardial blood flow (MBF) was measured with [(13)N]ammonia and positron emission tomography at rest, during cold pressor testing (CPT), and during adenosine hyperaemia. In diabeticpatients, MBF and blood chemistry were analysed again after 3 months of glucose-lowering treatment with glyburide and metformin. RESULTS: Although hyperaemic MBF did not differ significantly between the patients and controls (1.81 (0.38) v 1.97 (0.43) ml/min/g; mean (SD)), the CPT-induced MBF increase (DeltaMBF) was significantly less in diabeticpatients than in controls (0.07 (0.07) v 0.25 (0.12) ml/min/g; p<0.001). Treatment with glyburide and metformin significantly decreased plasma glucose concentrations from 207 (76) to 134 (52) mg/dl (p<0.001). This decrease in plasma glucose was paralleled by a significant increase in DeltaMBF in response to CPT (0.20 (0.16) from 0.07 (0.07) ml/min/g; p<0.001), which tended to be lower than in controls at baseline (0.20 (0.16) v 0.25 (0.12) ml/min/g; p = NS). The decrease in plasma glucose concentrations correlated significantly with the improvement in DeltaMBF in response to CPT (r = 0.67, p<0.01). CONCLUSIONS: Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin. The close association between the decrease in plasma glucose concentration and the improvement in coronary vasomotor function in response to CPT suggests a direct adverse effect of raised plasma glucose concentration on diabetes-related coronary vascular disease.
Authors: M F Di Carli; D Bianco-Batlles; M E Landa; A Kazmers; H Groehn; O Muzik; G Grunberger Journal: Circulation Date: 1999-08-24 Impact factor: 29.690
Authors: U Hink; H Li; H Mollnau; M Oelze; E Matheis; M Hartmann; M Skatchkov; F Thaiss; R A Stahl; A Warnholtz; T Meinertz; K Griendling; D G Harrison; U Forstermann; T Munzel Journal: Circ Res Date: 2001-02-02 Impact factor: 17.367
Authors: Thomas H Schindler; Egbert U Nitzsche; Heinrich R Schelbert; Manfred Olschewski; James Sayre; Michael Mix; Ingo Brink; Xiao-Li Zhang; Michael Kreissl; Nobuhisa Magosaki; Hanjoerg Just; Ulrich Solzbach Journal: J Am Coll Cardiol Date: 2005-05-03 Impact factor: 24.094
Authors: Rodica Pop-Busui; Ian Kirkwood; Helena Schmid; Victor Marinescu; Justin Schroeder; Dennis Larkin; Elina Yamada; David M Raffel; Martin J Stevens Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Sharyn M Fitzgerald; Barbara K Kemp-Harper; Marianne Tare; Helena C Parkington Journal: Clin Exp Pharmacol Physiol Date: 2005 May-Jun Impact factor: 2.557
Authors: Thomas H Schindler; Jerson Cardenas; John O Prior; Alvaro D Facta; Michael C Kreissl; Xiao-Li Zhang; James Sayre; Magnus Dahlbom; Julio Licinio; Heinrich R Schelbert Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Thomas H Schindler; Xiao-Li Zhang; Gabriella Vincenti; Leila Mhiri; René Lerch; Heinrich R Schelbert Journal: J Nucl Cardiol Date: 2007-07 Impact factor: 5.952
Authors: Vincent Dunet; François Feihl; Amin Dabiri; Gilles Allenbach; Bernard Waeber; Raphaël Heinzer; John O Prior Journal: Eur J Nucl Med Mol Imaging Date: 2015-08-19 Impact factor: 9.236
Authors: Thomas H Schindler; Jerson Cadenas; Alvaro D Facta; Yanjie Li; Manfred Olschewski; James Sayre; Jonathan Goldin; Heinrich R Schelbert Journal: Eur Heart J Date: 2009-12 Impact factor: 29.983